Greater Cannabis Co Inc. · OTC:GCAN
Greater Cannabis — Investor Presentation (January 2019)
16 slides from Greater Cannabis's investor presentation, January 2019
Slide 1: Cannabis Delivery of the Future
Cannabis Delivery of the Future Corporate Presentation JANUARY 2019
Slide 2: Forward Looking Statements
Forward Looking Statements Except for the historical information contained herein, the matters discussed in this presentation are forward looking statements within the meaning of the federal securities laws. Important factors could cause our actual results to differ materially from those contained i
Slide 3: GCANRx is a biopharmaceutical company focused on cannabinoid delivery systems
GCANRx is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems. GCANRx leverages its patented technology platform, which has been successfully used in other drug delivery applications, for the benefit of cannabis patients and consume
Slide 4: Cannabis use is growing exponentially, projected to surpass $32B in 2022
Cannabis use is growing exponentially, projected to surpass $32B in 2022. Legal Cannabis Spending (In Billions) $3.1 $2.4 $5.5 $1.5 $4.5 $23.4 $1.0 $3.6 $20.9 $0.6 $2.7 $17.8 $0.4 $1.3 $14.4 $0.6 $11.0 $8.5 Canada United States Rest of World Arcview Market Research/BDS Analytics 4 CORPORATE PRESENTA
Slide 5: Current cannabis delivery systems are severely lacking
However, current cannabis delivery systems are severely lacking. Inefficient Absorption Inaccurate Dosing Unhealthy Side Effects Inhalation: Bioavailability following the Inaccurate/Unpredictable Dosing: Cannabis Smoke: Similar to smoking tobacco, these include smoking route was reported as 2−56%, d
Slide 6: GCANRx's Eluting Patch Platform (EPP)
GCANRx’s Eluting Patch Platform (EPP) Our eluting patch platform (EPP) is an orally dissolving transmucosal thin film. Its multilayer system enables multiple cannabinoids and different dosages to be loaded onto the same patch, and delivered in pre-set intervals. • Easy-to-use (fully dissolvable) • N
Slide 7: Technology enables quicker effects with lower, more accurate dosing
GCANRx’s technology enables quicker desired effects with a lower, and more accurate, standardized dosing. GCANRx’s delivery platform can be utilized to deliver cannabis actives directly into the body without the harmful side effects of smoking or vaping, and with quicker onset and greater bioavailab
Slide 8: Buccal Application: The patch is easy to use
Buccal Application: The patch is easy to use – just open and stick to the cheek. 8 CORPORATE PRESENTATION / JANUARY 2019
Slide 9: The patch has multiple layers and enables different dosages
The patch has multiple layers and enables different dosages. Towards the oral cavity Towards buccal / gum tissue 9 CORPORATE PRESENTATION / JANUARY 2019
Slide 10: GCANRx's patch has several advantages
GCANRx’s patch has several advantages. Multi-layer and multi-purpose Rapid onset with slow, fast, and film that’s flexible and thin sustained release High active material loading capacity Needle-free intra-oral systemic drug (50 mg) delivery Bioadhesive and fully orally Easy, clean, and discrete adm
Slide 11: Eluting Patch Platform studied with support from the National Institutes of Health
GCANRx's Eluting Patch Platform has been studied with support from the National Institutes of Health. Clinical pharmacokinetic studies were conducted and published in conjunction with Penn State School of Medicine. Results showed the eluting patch delivery as an novel delivery system was well tolera
Slide 12: DEA-approved research and manufacturing lab in New Brunswick, New Jersey
Our DEA-approved research and small scale manufacturing lab is located in New Brunswick, New Jersey. Biotechnology Development Center in New Brunswick, New Jersey 12 CORPORATE PRESENTATION / JANUARY 2019
Slide 13: Our IP assets are centered around cutting-edge delivery technologies
Our IP assets are centered around cutting-edge delivery technologies. WO 2010/135053 A2 (IP from Pharmedica Ltd) • Dual and single layer dosage forms. • Issued US patent on April 28, 2015. US 62/737,153 • Oral dissolving film for rapid and sustained release and delivery of Cannabinoids. • Provisiona
Slide 14: Commercializing the technology in the global market through partnerships
GCANRx is focused on commercializing its technology in the global market through both medical and recreational uses. This will be done through partnerships with leading: Cannabis Licensed Consumer Pharmaceutical Companies Focused Producers/Processors Products Brands on Cannabinoids Therapies We part
Slide 15: Management has the business and technical acumen to build a high-growth business
Management has the business and technical acumen to build a high-growth business. AITAN ZACHARIN MARK RADOM, ESQ DR HOCK TAN, PH.D DAVID TAVOR CEO & Director VP & General Counsel Chairman, Director & Active • Experienced executive with broad • Served as a C-level executive of numerous Scientific Adv
Slide 16: GCANRx Success Through Innovation
GCANRx Success Through Innovation. CONTACT US info@gcanrx.com gcanrx.com 16 CORPORATE PRESENTATION / JANUARY 2019
Greater Cannabis — Investor Presentation (January 2019) on 6ix